Clinical trials
Endometrial Cancer Recurrent clinical trials
Below are recruiting endometrial cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 119 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07027046Recruiting
A new robotic tool for endometrial cancer surgery
This trial is testing a newer, single-port robotic system (da Vinci SP) for staging surgery in endometrial cancer. It aims to see if this system is safe and effective for removing the uterus, ovaries, and possibly lymph nodes, with less scarring.
Naples, NapoliAges 18 years+ - NCT07022483RecruitingPhase 3
New drug vs standard chemo for HER2-positive endometrial cancer
This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.
Fort Lauderdale, FloridaAges 18 years+ - NCT06989112RecruitingPhase 3
First-line treatment for advanced or recurrent endometrial cancer
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
Tucson, ArizonaAges 18 years+ - NCT06855706Recruiting
Personalized physical activity program for ovarian and endometrial cancers
This study tests whether a personalized, automated physical activity program (using a Fitbit and continuous glucose monitor) can improve immune function and health outcomes in people with advanced ovarian, primary peritoneal, fallopian tube, or newly diagnosed endometrial cancer. You'll wear an activity tracker, answer questionnaires, and provide blood and stool samples at Roswell Park.
Buffalo, New YorkAges 18 years+ - NCT06795009RecruitingPhase 1
Zanzalintinib plus paclitaxel for recurrent uterine cancer
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
San Francisco, CaliforniaAges 18 years+ - NCT06781151Recruiting
Personalized treatment for recurrent gynecologic cancers
This study tests if personalized treatment plans, based on detailed genetic testing of your tumor, can help women with recurrent ovarian, cervical, or endometrial cancer. You will work with a team of specialists to find the best options for you.
Guangzhou, GuangdongAges 18 years+ - NCT06712472RecruitingPhase 3
Testing maintenance olaparib versus observation after chemoradiation for p53 abnormal endometrial cancer
This trial tests whether taking a daily pill called olaparib after standard chemoradiation can help prevent endometrial cancer with a p53 mutation from coming back. Half of participants will receive olaparib, and the other half will just be watched closely.
AlbiAges 18 years+ - NCT06677190RecruitingPhase 2
Belzutifan for Recurrent Clear Cell Gynecologic Cancer
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Boston, MassachusettsAges 18 years+ - NCT06553612Recruiting
Supportive care planning after gynecological cancer treatment
This study compares a special day-hospital visit focused on supportive care needs to standard follow-up for people who have finished initial treatment for ovarian or endometrial cancer. The goal is to see if the special visit helps more people get the supportive care they need.
BesançonAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Phoenix, ArizonaAges 18–70 - NCT06463028RecruitingPhase 2
Targeted pills plus chemo for advanced endometrial cancer
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
La Jolla, CaliforniaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT05049538Recruiting
Liquid blood tests to predict endometrial cancer return
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Houston, TexasAges 18 years+
Hear when a new Endometrial Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for endometrial cancer recurrent?
- Yes. Clin2 currently lists 119 recruiting endometrial cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a endometrial cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a endometrial cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.